Skip to main content

LNCRNAS: NUEVAS DIANAS PARA EL TRATAMIENTO DEL MIELOMA MULTIPLE MEDIANTE QUIMERAS APTAMERO-SIRNAS.

PI19/01352

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2019
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION INSTITUTO DE INVESTIGACION SANITARIA DE NAVARRA
Execution centre INSTITUTO DE INVESTIGACION SANITARIA DE NAVARRA (IdISNA)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publication Artículo científico (JournalArticle)

Assessment of minimal residual disease by next generation sequencing in peripheral blood as a complementary tool for personalized transplant monitoring in myeloid neoplasms

  • Aguirre-Ruiz, Paula
  • Ariceta, Beñat
  • Viguria Alegría, María Cruz
  • Zudaire, María Teresa
  • Blasco-Iturri, Zuriñe
  • Arnedo, Patricia
  • Aguilera-Diaz, Almudena
  • Jauregui, Axier
  • Mañú, Amagoia
  • Prósper, Felipe
  • Mateos, María Carmen
  • Fernández-Mercado, Marta
  • Larráyoz, María José
  • Redondo, Margarita
  • Calasanz, María José
  • Bandrés Elizalde, Eva
  • Vázquez Urio, Iria
Patients with myeloid neoplasms who relapsed after allogenic hematopoietic stem cell transplant (HSCT) have poor prognosis. Monitoring of chimerism and specific molecular markers as a surrogate measure of relapse is not always helpful; therefore, improved systems to detect early relapse are needed. We hypothesized that the use of next generation sequencing (NGS) could be a suitable approach for personalized follow-up post-HSCT. To validate our hypothesis, we analyzed by NGS, a retrospective set of peripheral blood (PB) DNA samples previously evaluated by high-sensitive quantitative PCR analysis using insertion/deletion polymorphisms (indel-qPCR) chimerism engraftment. Post-HCST allelic burdens assessed by NGS and chimerism status showed a similar time-course pattern. At time of clinical relapse in 8/12 patients, we detected positive NGS-based minimal residual disease (NGS-MRD). Importantly, in 6/8 patients, we were able to detect NGS-MRD at time points collected prior to clinical relapse. We also confirmed the disappearance of post-HCST allelic burden in non-relapsed patients, indicating true clinical specificity. This study highlights the clinical utility of NGS-based post-HCST monitoring in myeloid neoplasia as a complementary specific analysis to high-sensitive engraftment testing. Overall, NGS-MRD testing in PB is widely applicable for the evaluation of patients following HSCT and highly valuable to personalized early treatment intervention when mixed chimerism is detected., This work was funded by the Government of Navarra, Department of Industry, Energy and Innovation (Project DIANA, 0011-1411-2017-000028); and supported by CIMA LAB diagnostics research program. F.P. acknowledges funding from Instituto de Salud Carlos III (ISCIII) PI16/02024, PI17/00701 and PI19/01352 (Co-financed with European Union FEDER funds), CIBERONC CB16/12/00489 (Co-financed with European Union FEDER funds), MINECO Explora (RTHALMY), Departamento de Salud-Gobierno de Navarra 40/2016 and Fundación Ramón Areces (PREMAMM).
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone disease

  • García Gómez, Antonio
  • Li, Tianlu|||0000-0001-7152-4870
  • de la Calle-Fabregat, Carlos|||0000-0002-3026-3069
  • Rodríguez-Ubreva, Javier|||0000-0003-4707-4536
  • Ciudad, Laura|||0000-0002-5219-6792
  • Català-Moll, Francesc|||0000-0002-2354-8648
  • Godoy-Tena, Gerard|||0000-0003-3832-5794
  • Martín Sánchez, Montserrat
  • San Segundo, Laura|||0000-0003-2391-5935
  • Muntión, Sandra|||0000-0001-7164-0767
  • Morales Urteaga, Xabier|||0000-0003-0303-9958
  • Ortiz de Solórzano, Carlos|||0000-0001-8720-0205
  • Oyarzabal, Julen|||0000-0003-1941-7255
  • San José Enériz, Edurne|||0000-0001-5786-5273
  • Esteller, M|||0000-0003-4490-6093
  • Agirre, Xabier|||0000-0002-6558-9560
  • Prosper, Felipe|||0000-0001-6115-8790
  • Garayoa, Mercedes|||0000-0003-2194-2841
  • Ballestar, Esteban|||0000-0002-1400-2440
Multiple myeloma (MM) progression and myeloma-associated bone disease (MBD) are highly dependent on bone marrow mesenchymal stromal cells (MSCs). MM-MSCs exhibit abnormal transcriptomes, suggesting the involvement of epigenetic mechanisms governing their tumor-promoting functions and prolonged osteoblast suppression. Here, we identify widespread DNA methylation alterations of bone marrow-isolated MSCs from distinct MM stages, particularly in Homeobox genes involved in osteogenic differentiation that associate with their aberrant expression. Moreover, these DNA methylation changes are recapitulated in vitro by exposing MSCs from healthy individuals to MM cells. Pharmacological targeting of DNMTs and G9a with dual inhibitor CM-272 reverts the expression of hypermethylated osteogenic regulators and promotes osteoblast differentiation of myeloma MSCs. Most importantly, CM-272 treatment prevents tumor-associated bone loss and reduces tumor burden in a murine myeloma model. Our results demonstrate that epigenetic aberrancies mediate the impairment of bone formation in MM, and its targeting by CM-272 is able to reverse MBD.